359 related articles for article (PubMed ID: 36950251)
1. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
2. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Suzuki Y; Watanabe M; Matsui T; Motoya S; Hisamatsu T; Yuasa H; Tabira J; Isogawa N; Tsuchiwata S; Arai S; Hibi T
Inflamm Intest Dis; 2019 Oct; 4(4):131-143. PubMed ID: 31768386
[TBL] [Abstract][Full Text] [Related]
4. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
5. P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
Parra Izquierdo V; Frias-Ordoñez J; Galindo P; Romero-Sanchez C; Florez C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S14-S15. PubMed ID: 37461974
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
[TBL] [Abstract][Full Text] [Related]
7. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
Parra RS; Chebli JMF; de Azevedo MFC; Chebli LA; Zabot GP; Cassol OS; de Sá Brito Fróes R; Santana GO; Lubini M; Magro DO; Imbrizi M; Moraes ACDS; Teixeira FV; Alves Junior AJT; Gasparetti Junior NLT; da Costa Ferreira S; Queiroz NSF; Kotze PG; Féres O
Crohns Colitis 360; 2024 Apr; 6(2):otae023. PubMed ID: 38681979
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37843044
[TBL] [Abstract][Full Text] [Related]
11. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study.
Ma C; Panaccione R; Xiao Y; Khandelwal Y; Murthy SK; Wong ECL; Narula N; Tsai C; Peerani F; Reise-Filteau M; Bressler B; Starkey SY; Loomes D; Sedano R; Jairath V; Bessissow T;
Am J Gastroenterol; 2023 May; 118(5):861-871. PubMed ID: 36580497
[TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.
Taxonera C; Olivares D; Alba C
Inflamm Bowel Dis; 2022 Jan; 28(1):32-40. PubMed ID: 33586766
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran.
Jameshorani M; Vahedi H; Sadeghi A; Sima AR; Anushiravani A; Nateghi Beige H; Malekzadeh MM; Naserinejad S; Alatab S
Arch Iran Med; 2021 May; 24(5):354-363. PubMed ID: 34196200
[TBL] [Abstract][Full Text] [Related]
14. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
[TBL] [Abstract][Full Text] [Related]
15. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.
Ledder O; Dolinger M; Dubinsky MC; Stein R; Vellanki S; Buckuk R; Fatima A; Suskind DL; Scarlett J; Röser D; Shouval DS; Meyer G; Rios ZM; Pujol-Muncunill G; Lozano A; Kolho KL; Rohani P; Hussey S; de Mejj T; Ayers T; Navas-López VM; Turner D; Tzivinikos C
Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38828483
[TBL] [Abstract][Full Text] [Related]
18. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Matsuoka K; Hisamatsu T; Kim HJ; Ye BD; Arai S; Hoshi M; Yuasa H; Tabira J; Toyoizumi S; Shi N; Woo JS; Hibi T
J Gastroenterol Hepatol; 2022 Oct; 37(10):1884-1892. PubMed ID: 35734858
[TBL] [Abstract][Full Text] [Related]
20. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
Armuzzi A; Hart A; Cappelleri JC; Mammar N; Hur P; Hoskin B; Hennessy F; Milligan G; Dignass A
BMC Gastroenterol; 2023 Jan; 23(1):17. PubMed ID: 36658481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
